Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132807 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 20
- Study locations
NCT01132807: Completed Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
NCT01132807 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 164 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01132807, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well chemotherapy based on positron emission tomography (PET) scan works in treating patients with stage I or stage II Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started. Comparing results of diagnostic procedures, such as PET scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Primary Outcome
The primary objective of this trial is to estimate the 3 year PFS in patients who received 4 cycles of ABVD. PFS for each patient is measured as the time from registration on trial to the first incident of death or progression. The PFS at 36 months is calculated as the number of patients who have a progression-free survival time greater than 36 months divided by the total number of patients that started treatment. For this endpoint, all patients that received 4 cycles of doxorubicin, bleomycin,
Conditions Studied
Interventions
- DRUG Doxorubicin Hydrochloride
- BIOLOGICAL Bleomycin Sulfate
- DRUG Dacarbazine
- DRUG Vinblastine Sulfate
- DRUG Procarbazine Hydrochloride
Study Locations (20)
Hawaii
- OnCare Hawaii, Incorporated - Lusitana - Honolulu
- Queen's Cancer Institute at Queen's Medical Center - Honolulu
- Straub Clinic and Hospital, Incorporated - Honolulu
- OnCare Hawaii, Incorporated - Kuakini - Honolulu
- Kuakini Medical Center - Honolulu
- Kapiolani Medical Center for Women and Children - Honolulu
- Castle Medical Center - Kailua
- Kauai Medical Clinic - Lihue
- Kapiolani Medical Center at Pali Momi - ‘Aiea
- Oncare Hawaii, Incorporated - Pali Momi - ‘Aiea
Illinois
- Mount Sinai Hospital Medical Center - Chicago
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
- John H. Stroger, Jr. Hospital of Cook County - Chicago
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
California
- City of Hope Comprehensive Cancer Center - Duarte
Connecticut
- Yale Cancer Center - New Haven
Delaware
- CCOP - Christiana Care Health Services - Newark
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
Florida
- M.D. Anderson Cancer Center at Orlando - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2010-05 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
What the finished NCT01132807 record still lists
NCT01132807 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin Hydrochloride is the first listed.
NCT01132807 names 20 study sites across 9 states, led by Hawaii, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT01132807 about?
NCT01132807 is a clinical study titled "Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma". This phase II trial studies how well chemotherapy based on positron emission tomography (PET) scan works in treating patients with stage I or stage II Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping th...
What is the current status of trial NCT01132807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2010-05. Estimated completion is 2018-01.
What conditions does trial NCT01132807 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT01132807?
The interventions under investigation include: Doxorubicin Hydrochloride (DRUG), Bleomycin Sulfate (BIOLOGICAL), Dacarbazine (DRUG), Vinblastine Sulfate (DRUG), Procarbazine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01132807?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01132807 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01132807's enrollment target sits among peer trials
164 57th of 299 higher than 243 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia